Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3830MR)

This product GTTS-WQ3830MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3830MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14407MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ4898MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ902MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ1557MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ12770MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ8657MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ3442MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ13938MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW